<DOC>
	<DOCNO>NCT00626743</DOCNO>
	<brief_summary>To assess pharmacodynamic effect co-administrated SK3530 ( PDE5 inhibitor ) Amlodipine , phase I study Hypertensive patient design .</brief_summary>
	<brief_title>Phase I Study Investigate Effect Blood Pressure After Oral Administration SK3530 Amlodipine</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Male subject 1965 year age inclusive Subjects hypertension define 100 mmHg ≤ SBP &lt; 140 mmHg 65 mmHg ≤ DBP &lt; 90 mmHg 5 minute supine position Written informed consent Willing able comply requirement protocol Subjects acute chronic disease within 4 week study initiation . Subejcts gastrointestinal disorder know alter drug absorption ( except appendectomy , herniotomy , etc . ) Subjects clinically significant allergic disease know allergy PDE5 inhibitor Subjects clinically significant abnormality laboratory test Subjects orthostatic hypotension define fall systolic blood pressure least 20 mmHg diastolic blood pressure least 10 mmHg person assume stand position Subjects abnormal QTc interval ( ≥440ms ) Subjects colorblindness weakness Subejcts alcohol , drug caffeine abuse Diet known alter drug absorption , distribution , metabolism elimination process Subjects participate clinical study within 2 month administration Other subject ineligible study discretion principle investigator subinvestigators</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>